Next Investors logo grey

Abundant Produce joins forces with Australia’s leading healthcare service provider

Published 23-FEB-2018 12:43 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Abundant Produce (ASX:ABT) today revealed it has penned a sales, marketing and distribution agreement with HealthOne, which will commence in Australia.

This deal will see HealthOne representing Abundant Natural Health (ANH) products in Australian pharmacies servicing independent pharmacies and gift outlets.

HealthOne is Australia’s fastest growing healthcare commercial partner, with specialist national sales teams servicing all facets of the pharmacy channel, leveraging robust relationships with wholesalers, key banner groups, individual pharmacies and healthcare professionals.

It has been active in the Australian healthcare marketplace for over 15 years, representing market-leading companies and brands. Its multi‐dimensional approach encompasses brand strategy, marketing services, sales representation, merchandising, and staff education.

ABT CEO, Shanan Birkin, said: “Importantly, our agreement with HealthOne moves us from an online platform to a bricks-and-mortar presence with a partner that has the ability to penetrate the Australian market, using its in‐depth understanding of the intricacies of pharmacy product distribution.”

Birkin added: “This helps us to build on our objective of becoming a number-one player in the natural healthcare arena and the ethical brand of choice. We believe our 100% Australian grown, made and owned products are a game changer in our target markets.”

HealthOne managing director, Seona Wallace, commented: “We’re excited about representing these new innovative products, which are developed and produced locally by ANH in collaboration with the University of Sydney and the University of NSW.”

“Having science-based products of this calibre, particularly the new body and skin ranges, will be a great offering to the majors,” said Wallace.

It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.